Compare AGIO & ETV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGIO | ETV |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2013 | N/A |
| Metric | AGIO | ETV |
|---|---|---|
| Price | $27.39 | $14.20 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $32.13 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 252.5K |
| Earning Date | 10-30-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.75% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,791,000.00 | N/A |
| Revenue This Year | $28.75 | N/A |
| Revenue Next Year | $139.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.26 | N/A |
| 52 Week Low | $22.24 | $11.05 |
| 52 Week High | $46.00 | $13.50 |
| Indicator | AGIO | ETV |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 46.95 |
| Support Level | $26.80 | $14.20 |
| Resistance Level | $28.61 | $14.45 |
| Average True Range (ATR) | 1.19 | 0.17 |
| MACD | 0.25 | 0.00 |
| Stochastic Oscillator | 56.00 | 39.20 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.